Pfizer to end license deal with Syros for blood disorder therapies

Syros Pharmaceuticals

21/07/2023 22:40

July 21 (Reuters) - Syros Pharmaceuticals  SYRS.O  said
on Friday Pfizer  PFE.N  will terminate a license deal between
the companies related to the development of novel therapies for
two blood disorders. 
    Shares of Syros were down 5.7% in trading after the bell.
    The termination will end the company's more than three-year
long collaboration with sickle cell disease drugmaker Global
Blood Therapeutics (GBT) that Pfizer bought in a $5.4 billion
deal last August.
    The partnership for sickle cell disease and beta thalassemia
- diseases that affect the production and nature of hemoglobin
in the blood is set to end on Oct. 16, the company said.
    Syros "intends to seek to identify a new out-licensing
partner for its sickle cell disease program," it added.

 (Reporting by Sriparna Roy and Savyata Mishra in Bengaluru;
Editing by Shailesh Kuber)
 ((Sriparna.Roy@thomsonreuters.com;))